Tiotropium Bromide

CAS 136310-93-5

About the API

Systematic name (1, 2, 4, 5, 7)-7-[(Hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[,4] nonane bromide
Trade name(s) Spiriva
Molecular Formula C19H22BrNO4S2
Molecular Weight 472.42 g/mol
Physical properties white or yellowish white powder
Therapeutic category Respiratory
Available formulations Inhalation
Regulations EU DMF Flag EU DMF US DMF Flag US DMF

General Information

Tiotropium bromide belongs to a class of drugs termed bronchodilators and is used to alleviate breathing difficulties associated with chronic obstructive pulmonary disease (COPD). Specifically, COPD can cause symptoms such as shortness of breath, coughing, wheezing, and chest tightness.

Tiotropium bromide is an anticholinergic agent, which means it blocks the neurotransmitter acetylcholine. Anticholinergic agents increase the ease of breathing by relaxing bronchial smooth muscle, dilating the lungs, and reducing bronchospasms.

Tiotropium bromide is dispensed as a powder contained in a capsule and administered using a specially designed inhaler that allows the patient to breath in the powdered drug.

It is not used for acute attacks, but rather chronic conditions that have persistent symptoms requiring long-acting treatment.


Tiotropium bromide became FDA approved for the treatment of bronchial spasms in patients with chronic obstructive pulmonary disease (COPD) under the trade name Spiriva in 2004.

It is currently manufactured through large-scale synthetic organic chemistry methods starting from simple, commercially available precursors.